Unexpected Primaquine-Induced Hemolysis in a G6PD-Normal Patient: A Case Report From Nepal
- PMID: 40062310
- PMCID: PMC11888929
- DOI: 10.1002/ccr3.70303
Unexpected Primaquine-Induced Hemolysis in a G6PD-Normal Patient: A Case Report From Nepal
Abstract
Primaquine, an antimalarial drug, is essential for preventing relapses of Plasmodium vivax. However, it poses a risk of hemolytic anemia, particularly in glucose-6-phosphate dehydrogenase (G6PD) deficient patients. This case report details a 27-year-old male with normal G6PD levels who developed hemolytic anemia following primaquine therapy for P. vivax malaria. Despite a normal quantitative G6PD analysis, the patient experienced a significant drop in hemoglobin, necessitating early discontinuation of the drug. This case highlights the potential for hemolysis in G6PD-normal patients, underscoring the importance of close monitoring and the limitations of current G6PD screening methods.
Keywords: general medicine; hematology; infectious diseases; toxicology.
© 2025 The Author(s). Clinical Case Reports published by John Wiley & Sons Ltd.
Conflict of interest statement
The authors declare no conflicts of interest.
References
-
- WHO , “Guidelines for Malaria—3 June 2022,” 2022.
LinkOut - more resources
Full Text Sources
Miscellaneous
